- 15-0457-42 - Invitrogen Antibodies PTPRC antibody

Submitted references Longitudinal analysis of subtype C envelope tropism for memory CD4(+) T cell subsets over the first 3 years of untreated HIV-1 infection.

Gartner MJ, Gorry PR, Tumpach C, Zhou J, Dantanarayana A, Chang JJ, Angelovich TA, Ellenberg P, Laumaea AE, Nonyane M, Moore PL, Lewin SR, Churchill MJ, Flynn JK, Roche M
Retrovirology 2020 Aug 6;17(1):24

Single-cell profiling reveals GPCR heterogeneity and functional patterning during neuroinflammation.

Tischner D, Grimm M, Kaur H, Staudenraus D, Carvalho J, Looso M, Günther S, Wanke F, Moos S, Siller N, Breuer J, Schwab N, Zipp F, Waisman A, Kurschus FC, Offermanns S, Wettschureck N
JCI insight 2017 Aug 3;2(15)

Blocking the recruitment of naive CD4(+) T cells reverses immunosuppression in breast cancer.

Su S, Liao J, Liu J, Huang D, He C, Chen F, Yang L, Wu W, Chen J, Lin L, Zeng Y, Ouyang N, Cui X, Yao H, Su F, Huang JD, Lieberman J, Liu Q, Song E
Cell research 2017 Apr;27(4):461-482

Functional expression of CD137 (4-1BB) on T helper follicular cells.

Alfaro C, Echeveste JI, Rodriguez-Ruiz ME, Solorzano JL, Perez-Gracia JL, Idoate MA, Lopez-Picazo JM, Sanchez-Paulete AR, Labiano S, Rouzaut A, Oñate C, Aznar A, Lozano MD, Melero I
Oncoimmunology 2015 Dec;4(12):e1054597

No comments: Submit comment

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Staining of normal human peripheral blood cells with staining buffer (autofluorescence) (open histogram) or Anti-Human CD45RO PE-Cyanine5 (filled histogram).Cells in the lymphocyte gate were used for analysis.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 3 Transitional memory and effector memory cells were most frequently infected by C-HIV Envs. a Each data point represents the percentage of infected CD4 + T cells with one pseudovirus (averaged from four independent seronegative blood bank donors). The Env donor is indicated as follows; CAP88 (blue circles), CAP177 (red squares), CAP228 (green triangles), CAP255 (purple inverted triangles) and CAP257 (orange diamonds). Black lines represents the median of all pseudoviruses within each time point. Comparisons were made using a Kruskal-Wallis test with Dunn's post hoc test for multiple comparisons. b Stacked bar graphs represent the contribution of each T cell subset to the pool of infected CD4 + T cells. Values represent the median percentage of infected CD4 + T-cells (averaged across four HIV-seronegative PBMC donors) that belong to the indicated subset [naive; dark blue, T stem cell memory (TSCM); red, central memory (CM); yellow, transitional memory (TM); light blue, effector memory (EM); purple and terminally differentiated (TD); green], and are stratified by participant and time point. Error bars represent the interquartile range. c Dot plot representing the proportion of each T cell subset contributing to the total pool of infected cells for all Env-pseudoviruses. Each point represents a single virus averaged across four seronegative donors, lines represent median and error bars represent interquartile range. Comparisons were made using a Kruskal-Wallis test with Du

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 5 PITPNM3 is a CCL18 receptor on naive CD4 + T cells. (A) Representative flow cytometry staining for PITPNM3 and CCR8, potential CCL18 receptors, on gated PB T cell subsets and paired TI naive CD4 + T cells of a breast cancer patient. Cells were gated on CD3 + CD45RA + CD45RO - CD25 - CD4 + /CD8 + for naive CD4 + /CD8 + T cells, CD3 + CD45RA - CD45RO + CD25 - CD4 + /CD8 + for memory CD4 + /CD8 + T cells and CD3 + CD4 + CD25 + for Tregs). Quantitation of PITPNM3 and CCR8 expression on T cell subsets for eight breast cancer patients is provided in Supplementary information, Figure S8A . (B-F) Knockdown of PITPNM3 in naive CD4 + T cells inhibits CCL18 binding, signaling and chemotaxis. (B) Binding of 125 I-CCL18 to naive CD4 + T cells, knocked down or not for PITPNM3 (shPI-1,2) in the presence of increasing concentrations of unlabeled CCL18. Shown are the representative assays for three independent experiments using PB T cells from three normal donors. (C) Representative fluorescence microscopy images of CCL18 binding to naive CD4 + T cells, knocked down or not for PITPNM3 , stained for PITPNM3 and CCL18 3 h after adding CCL18. Scale bar, 5 mum. Shown are the representative images for three independent experiments using PB T cells from three normal donors. (D) Immunoblot of CCL18-treated naive CD4 + T cells, knocked down or not for PITPNM3 , showing expression of PITPNM3 and phosphorylated/total (t-) Erk1/2 and Akt, relative to GAPDH as a loading control. Blots are repres

15-0457-42

Antibody data